A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial

ConclusionLong-term follow-up evaluation confirmed that TPF followed by surgery is feasible and promising in terms of survival for BR-ESCC patients.Trial Registration ClinicalTrials.gov identifer: NCT02976909.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research